MDxHealth is trading at $0.55 (-8.88%) in after-hours trading after suspending its 2026 revenue guidance.
- Preliminary third-quarter revenue was approximately $22.7 million, flat year over year.
- Management said revenue fell short of expectations after unexpected sales-force turnover disrupted execution and forecasting.
- Tissue-based test volume fell 11% year over year; full results are expected November 12, 2026.